Profile Name | CSF1R V38M |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | CSF1R Y571D | myeloid leukemia | sensitive | Imatinib | Preclinical | Actionable | In a preclinical study, CSFR1 Y571D conferred sensitivity to Gleevec (imatinib) in myeloid cell lines in culture (PMID: 18971950). | 18971950 | CSF1R over exp | tenosynovial giant cell tumor | sensitive | Pexidartinib | Phase I | Actionable | In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558). | 26222558 | CSF1R positive | Hodgkin's lymphoma | not applicable | N/A | Clinical Study | Prognostic | In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918). | 24619759 26066800 22955918 | CSF1R positive | Hodgkin's lymphoma | sensitive | Sorafenib | Preclinical | Actionable | In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818) | 21517818 | BRAF V600E CSF1R positive | melanoma | sensitive | Pexidartinib + Vemurafenib | Preclinical | Actionable | In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769). | 25939769 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|